Xultophy 100/3.6 (insulin degludec and liraglutide injection)
Xultophy 100/3.6 (insulin degludec and liraglutide injection) combines ultra-long-acting insulin degludec with the glucagon-like peptide 1 (GLP-1) receptor agonist liraglutide and is used to improve blood glucose levels in adults with type 2 diabetes along with diet and exercise. Insulin degludec lowers blood glucose by helping glucose enter the cells to be used as fuel. Liraglutide helps release insulin when blood glucose rises at mealtime, lowers the amount of glucose produced by the liver, and slows the absorption of mealtime glucose.
Insulin degludec and liraglutide injection
Insulin + GLP-1 receptor agonists